- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00456313
No Resistance After Long Term Treatment SERETIDE
April 15, 2015 updated by: GlaxoSmithKline
Rationale for Therapy With Low Dose Steroids Combined With Long-acting beta2-agonists in Patients With Allergic Asthma: Redirecting Innate Immune Responses by Long-term Treatment With High Doses of Inhaled Steroids
This multi centre, double blind, comparator controlled, parallel group study is to determine whether asthma treatment with high doses of fluticasone propionate (FP) redirects a Th2/ eosinophil response towards a more treatment resistant neutrophil/ monocyte response and whether this occurs to a lesser extent in asthmatic subjects treated with the combination product of salmeterol and fluticasone propionate (SFC).
The primary endpoint is the mean change in priming of blood neutrophils assessed by marker A17.
After a run-in period of 4 weeks subjects will enter a 24 weeks high dose treatment (FP 500 mcg bd) or a 12 week medium-dose treatment with FP 250 mcg bd followed by a 12 week treatment with SFC 50/ 250 mcg.
At the visits lung function measurements, ACT, eNO measurements and a blood sample will be performed.
A total of 50 randomised subjects are planned to be recruited in this study
Study Overview
Study Type
Interventional
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Utrecht, Netherlands, 3584 CX
- GSK Investigational Site
-
Utrecht, Netherlands, 3582 KE
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion:
- Positive skin prick test
- History of asthma (GINA)
- Regular treatment with FP with/without LABA at least 4 weeks before visit 1
- History of recurrent episodes of wheezing, breathlessness, chest tightness and/ or coughing in the previous year.
- Able to use a DISKUS™ inhaler
- Able perform reproducible lung function tests at Visit 1
Inclusion criteria treatment period:
- FEV1 % predicted > 70%
- ACT score < 25 after run-in period
Exclusion criteria run-in period:
- Hospitalised for asthma within 4 weeks prior to Visit 1
- Acute upper respiratory tract infection or a lower respiratory tract infection within 4 weeks prior to Visit 1
- Oral, parental or depot corticosteroids within 4 weeks prior to Visit 1
- Hepatic impairment or other significant disease
Exclusion criteria treatment period:
- Non-compliance (< 70%)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: arm 1
|
comparator
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mean change in neutrophil priming in blood as assessed by marker A17
Time Frame: on going
|
on going
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Activation in markers such as A27, CD11b, L-selection, CD16, CD32, VLA-4 and CD66b in whole blood- Cytokine/chemokine determination by multiplex assay in cell free serum- Asthma control measured - Lung function: FEV1, FVC and PEF- eNO
Time Frame: on going
|
on going
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2007
Primary Completion (Anticipated)
December 1, 2007
Study Completion (Anticipated)
December 1, 2007
Study Registration Dates
First Submitted
April 3, 2007
First Submitted That Met QC Criteria
April 3, 2007
First Posted (Estimate)
April 4, 2007
Study Record Updates
Last Update Posted (Estimate)
April 17, 2015
Last Update Submitted That Met QC Criteria
April 15, 2015
Last Verified
April 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Immune System Diseases
- Lung Diseases
- Hypersensitivity, Immediate
- Bronchial Diseases
- Lung Diseases, Obstructive
- Respiratory Hypersensitivity
- Hypersensitivity
- Asthma
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Dermatologic Agents
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Anti-Allergic Agents
- Sympathomimetics
- Fluticasone
- Fluticasone-Salmeterol Drug Combination
Other Study ID Numbers
- SAM109352
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
-
Johann Wolfgang Goethe University HospitalCompletedExercise-induced AsthmaGermany
Clinical Trials on FLIXOTIDE and SERETIDE
-
Mundipharma Research LimitedCompletedAsthmaRussian Federation, Ukraine, Bulgaria, Czechia, Hungary, India, Poland, Romania
-
GlaxoSmithKlineCompleted
-
Brian J LipworthCompleted
-
GlaxoSmithKlineCompleted
-
Far Eastern Memorial HospitalCompleted
-
GlaxoSmithKlineCompleted
-
Orion Corporation, Orion PharmaCompleted
-
Mundipharma Research LimitedCompletedAsthma, BronchialHungary
-
Merck Sharp & Dohme LLCCompletedAcute Bacterial Skin and Skin Structure InfectionsUnited States, Brazil, Bulgaria, Georgia, Germany, Guatemala, Latvia, Lithuania, Mexico, Poland, Russian Federation, South Africa, Turkey, Ukraine